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Objectives We evaluated morphology and function of the gut in patients with chronic heart failure (CHF).
Background Intestinal translocation of bacterial endotoxin may contribute to the inflammatory state observed in patients
with CHF. The morphology and function of the gut may be abnormal.
Methods We studied 22 patients with CHF (age 67  2 years, left ventricular ejection fraction [LVEF] 31  1%, New York
Heart Association functional class 2.3  0.1, peak VO2 15.0  1.0 ml/kg/min) and 22 control subjects (62  1
years, LVEF 68  2%, peak VO2 24.7  1.3 ml/kg/min). Bowel wall thickness was assessed by transcutaneous
sonography, small intestinal permeability by the lactulose-mannitol test, passive carrier-mediated transport by
D-xylose test, large intestinal permeability by sucralose test (5- and 26-h urine collection, high-performance liq-
uid chromatography), and mucosal bacterial biofilm by fluorescence in situ hybridization in biopsies taken during
sigmoidoscopy.
Results Chronic heart failure patients, compared with control patients, showed increased bowel wall thickness in the
terminal ileum (1.48  0.16 mm vs. 1.04  0.08 mm), ascending colon (2.32  0.18 mm vs. 1.31  0.14
mm), transverse colon (2.19  0.20 vs. 1.27  0.08 mm), descending colon (2.59  0.18 mm vs. 1.43  0.13
mm), and sigmoid (2.97  0.27 mm vs. 1.64  0.14 mm) (all p  0.01). Chronic heart failure patients had a
35% increase of small intestinal permeability (lactulose/mannitol ratio: 0.023  0.001 vs. 0.017  0.001, p 
0.006), a 210% increase of large intestinal permeability (sucralose excretion: 0.62  0.17% vs. 0.20  0.06%,
p  0.03), and a 29% decrease of D-xylose absorption, indicating bowel ischemia (26.7  3.0% vs. 37.4 
1.4%, p  0.003). Higher concentrations of adherent bacteria were found within mucus of CHF patients com-
pared with control subjects (p  0.007).
Conclusions Chronic heart failure is a multisystem disorder in which intestinal morphology, permeability, and absorption are
modified. Increased intestinal permeability and an augmented bacterial biofilm may contribute to the origin of
both chronic inflammation and malnutrition. (J Am Coll Cardiol 2007;50:1561–9) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.016h
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fhronic heart failure (CHF) is a condition with a high
orbidity and mortality. Recent advances in understanding
he pathophysiology of CHF have led to the conclusion that
HF is a multisystem disorder that affects not only the
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ccepted July 17, 2007.eart and circulation but also the musculoskeletal, neuroen-
ocrine, metabolic, and immune systems. Chronic heart
ailure is now recognized as a state of chronic inflammation.
lasma levels of pro-inflammatory cytokines, such as tumor
ecrosis factor (TNF)-alpha, are long known to be related
o disease severity in CHF patients (1) and to predict poor
urvival (2). The origin of this inflammatory state is not well
nderstood (3), although several hypotheses have been put
orward. One hypothesis (4) is that much of the inflamma-
ory state arises from endotoxins entering the circulation
rom the gut.
Chronic heart failure leads to increased sympathetic activity,
hich contributes to a redistribution of blood flow away from
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patients, a decrease in intestinal
mucosal pH has been observed at
low levels of exercise, indicating
intestinal ischemia (5). Inadequate
mucosal perfusion increases intes-
tinal mucosal permeability (6). Li-
popolysaccharide (LPS) (endo-
toxin), a cell-wall component of
gram-negative bacteria, can enter
the circulation through the gut
wall if barrier function is impaired
in various diseases, such as burn
injury, sepsis, liver cirrhosis, and
ischemic reperfusion injury (7–10).
In the circulation of CHF pa-
tients, LPS may activate mono-
cytes and macrophages to release
pro-inflammatory mediators,
thus leading to an inflammatory
state. Elevated plasma concen-
rations of LPS have been found in CHF patients during
dematous decompensation (11). In acute heart failure,
ioactive LPS levels are higher in hepatic veins than in
he left ventricle (12). We hypothesized that intestinal
arrier dysfunction with an increased paracellular perme-
bility, a diminished transcellular transport activity, and
n augmented intestinal bacterial biofilm are present in
HF patients. We report here the changes in function
nd morphology of the gastrointestinal system in these
atients.
Abbreviations
and Acronyms
CHF  chronic heart failure
ELISA  enzyme-linked
immunosorbent assay
FISH  fluorescence in situ
hybridization
hs CrP  high-sensitivity
C-reactive protein
IL  interleukin
LPS  lipopolysaccharide
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
PI  permeability index
TNF  tumor necrosis
factor
VO2  oxygen consumption
Baseline Data for Caucasian Patients and Contr
Table 1 Baseline Data for Caucasian Patien
Cont
Number (women) 22
NYHA functional class
Ischemic etiology
Ejection fraction (%)
Age (yrs)
BMI (kg/m2) 2
Height (cm) 1
Weight (kg) 7
Peak VO2 (ml/min/kg) 2
Hemoglobin (g/dl) 1
Hematocrit (%) 3
White blood cells ( 109/l)
hs C-reactive protein (g/ml) 1.1
hs tumor necrosis factor-alpha (pg/ml)
hs interleukin-6 (pg/ml) 1.0
Sodium (mmol/l) 14
Potassium (mmol/l)
Creatinine clearance (ml/min) 8
ASAT (U/l) 2
ALAT (U/l) 2ALAT alanine aminotransferase; ASAT aspartate aminotransferase; BMI
NYHA  New York Heart Association.ethods
atients. We studied 22 CHF patients and 22 control
ubjects (for demographic and clinical details see Table 1).
he diagnosis of CHF was based on symptoms arising
uring exercise, clinical signs, and documented left ventricular
mpairment (left ventricular ejection fraction [LVEF]  40%)
ccording to current guidelines (13). All patients were clinically
table (New York Heart Association [NYHA] functional class
.3  0.1) and receiving unchanged medication for at least 4
eeks before assessments. Patients were allowed to take aspirin
00 mg once daily, but not other nonsteroidal anti-
nflammatory drugs or steroid hormones or antibiotics within
t least 4 weeks before being studied. In CHF patients,
edication consisted of angiotensin-converting enzyme inhib-
tors (77%), angiotensin receptor antagonists (23%), beta-
lockers (86%), diuretics (86%), glycosides (18%), and statins
77%) in varying combinations. None of the control subjects
as taking any medication except for calcium channel blocker
n 1 subject, angiotensin-converting enzyme inhibitors in 2
ubjects for mild arterial hypertension without evidence of left
entricular dysfunction, hormone replacement therapy in 1
ubject, and L-thyroxin in 2 subjects. Subjects with clinical
igns of infection, rheumatoid arthritis, renal failure, significant
alvular heart disease, intestinal diseases, cancer, or a history of
utoimmune disorders were excluded. None of the subjects had
ny known immune system disorders, and none received im-
une modulation therapy. The local ethics committee approved
he study, and all subjects gave written informed consent.
linical assessments. Echocardiography was performed
ollowing standard procedures. Left ventricular ejection
bjects
d Control Subjects
jects CHF Patients p Value
22 (4) 0.06
2.3 0.1
17/22
2 31 1 0.0001
1 67 2 0.054
1.0 27.8 1.0 0.3
9.9 174 8.8 0.5
3.3 84.4 4.5 0.2
1.3 15.0 1.0 0.0001
0.3 13.9 0.4 0.4
0.6 41.1 1.1 0.3
0.3 7.9 0.4 0.02
3.4) 2.1 (0.8, 3.6) 0.4
0.1 3.0 0.2 0.04
1.7) 3.0 (1.6, 3.4) 0.0002
0.6 142.0 1.1 0.6
0.1 4.4 0.4 0.8
4.0 74.8 5.9 0.07
1.5 30.9 2.4 0.06
2.9 28.2 3.6 0.3ol Su
ts an
rol Sub
(11)
68
62
6.2
72
7.5
4.7
3.4
9.8
6.7
(0.5,
2.5
(0.8,
1.4
4.3
7.9
3.1
5.3body mass index; CHF chronic heart failure; hs high sensitivity;
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October 16, 2007:1561–9 Intestinal Function in Chronic Heart Failureraction was measured using biplane Simpson’s technique.
our CHF patients had elevated right ventricular pressure,
ith 2 of them showing widened liver veins as a sign of
ongestion. One of these patients had a small amount of free
uid in the abdomen. All subjects underwent a symptom-
imited treadmill exercise testing (instantaneous breath-by-
reath method) using the modified Naughton protocol
MedGraphics CPX/D, Medical Graphics Corporation,
ardiorespiratory Diagnostic Systems, St. Paul, Minne-
ota). The following variables were measured: peak oxygen
onsumption (peak VO2), total exercise time, ventilatory
esponse to exercise (VE/VCO2 slope), anaerobic threshold,
eak heart rate (beats per minute), and peak systolic and
iastolic blood pressures.
Gastrointestinal permeability was assessed using a sugar-
rink test as previously described in detail (14). The test is
ased on the measurement of the urinary excretion of orally
dministered sugar-probe molecules. The lactulose/
annitol ratio (permeability index, PI) served as a marker
or intestinal permeability to avoid differences in variable
astric emptying, intestinal transit time during the first 5 h,
nd renal clearance (15,16). No drugs influencing gut
unction, including laxatives and antidiarrhoeal agents, were
aken by the subjects. Subjects were asked to refrain from
lcohol for at least 2 days before the study and from nicotine
n the morning before and during the test.
We performed 2 separate tests within an interval of at
east 4 days of each other. During the first test, which was
ompleted by 21 patients and 20 control subjects, each
ubject ingested capsules containing 5-g sucralose after an
vernight fast and drank a solution containing 10-g lactu-
ose, 5-g mannitol, and 20-g sucrose dissolved in 100 ml of
ater. Subjects were fasting during the first 5 h and were
ncouraged to drink water 2 h after the test started. Three
rine samples were taken: a before-test sample, a 5-h urine
ollection sample during the first 5 h after starting the test,
nd a 21-h urine collection sample of the following period
ntil 26 h after consumption. Gastroduodenal permeability
as analyzed by excretion of sucrose in the 5-h sample,
erving as a marker for gastroduodenal permeability (14).
mall intestinal permeability was assessed by the lactulose/
annitol ratio reflecting passive noncarrier-mediated trans-
ort (15,17). In the 5-h sample of the second oral sugar test,
e further assessed passive carrier-mediated transport in the
mall intestine by absorption of orally administered
-xylose. This test was completed in 22 patients and 21
ontrol subjects and performed within 6 days of sigmoidos-
opy. Large intestinal permeability was measured by sucra-
ose recovery in the third urine sample 5 to 26 h after
onsumption (18). In both tests, sodium acid was used as a
reservative for urine. Total urine volume was recorded on
ompletion of the test, and a 10-ml aliquot of each urine
ample was stored at –20°C until analysis.
For urine analysis, protein content was removed using
ulfosalicylic acid. Urine was then desalted with amberlite
ixed bed-3 resin. Sugars were separated using meso- srythritol, 2-deoxy-D-glucose and turanose as internal stan-
ards, analyzed and quantified by high-performance liquid
hromatography with pulsed electrochemical detection
Dionex, Idstein, Germany; chromatography module: 250 
0 mm Carbopac PA-1 column [Dionex]; eluent 150 mM
aOH/500 mM NaAC gradient; flow of 1 ml/min). Results
ere expressed as the percentage recovery of the ingested dose
f sugar.
Transcutaneous abdominal sonography (12-MHz linear-
rray transducer, HDI 5000, Philips, Belgium) was per-
ormed to assess intrabdominal free fluid and to measure
owel wall thickness in the middle segment of the sigmoid
in Subjects #1 to #44), descending, transverse, and ascend-
ng colon (Subjects #7 to #44). Measurement of the termi-
al ileum (Subjects #15 to #44) was performed 5 cm
roximal to the ileocecal valve. Because of obesity, the
ransverse colon was not assessed in 1 patient and the
ransverse and ascending colon in 1 other patient. Patients
ere scanned under identical conditions after overnight
asting. Measurement of bowel wall thickness was carried
ut in true cross and longitudinal sections of the relaxed
owel by assessment of the anterior bowel wall. Overall
hickness of the bowel wall was measured from the first
ucosal interface echo to the first serosal echo. Each
easurement was repeated 3 times at different positions of
he intestinal wall, and the mean was calculated. Arterial
lood flow velocities in the superior mesenteric artery and
he inferior mesenteric artery were assessed in all subjects by
n 8-5-MHz vector-array transducer. We did not detect any
tenoses of the mesenteric arteries in CHF patients or in
ontrol subjects. All recordings were performed in a stan-
ardized way, and readings were analyzed by the same
xperienced physician (J.B.), who was blinded as to the
ubjects’ study group. The intraobserver coefficient of vari-
tion for intestinal ultrasound measurements repeated on
onsecutive days is 5%. Accuracy of measurement is 0.2
m for all segments.
Flexible sigmoidoscopy was performed without sedation
fter a glycerol enema, except in 1 patient who declined this
art of the study. Biopsies of the sigmoid mucosa were taken
or fluorescence in-situ hybridization (FISH) as previously
escribed (18). In brief, biopsies were fixed in Carnoy
olution (19,20) and subjected to FISH evaluation on glass
lides. Oligonucleotide probes were synthesized with a Cy3
r Cy5 (carbocyanine) reactive fluorescent dye at the 5’ end
MWG Biotech, Ebersberg, Germany). A set of 38 FISH
robes at domain and group levels together with 1 species-
pecific probe for Helicobacter pylori was used (19). Density
f bacterial biofilm, spatial arrangement, and associative
ehavior of bacteria were investigated on 4-m-thick sec-
ions of biopsies. All analyses were carried out by 2 different
nvestigators in parallel who were unaware of the respective
ubject’s study group. One patient sample could not be
nalyzed because the amount of material from the biopsy
as too small. Digital pictures of bacteria on the micro-copic slide were taken with a Nikon DXM 1200 camera
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Intestinal Function in Chronic Heart Failure October 16, 2007:1561–9nd software (Nikon, Tokyo, Japan). We evaluated the
omposition of bacteria using multicolor FISH analysis.
wo group-specific probes labeled with Cy3 or Cy5 were
pplied simultaneously employing a universal Eub 338
ITC labeled probe. Bacteria positively hybridizing with
y3 (yellow fluorescence) or Cy5 (red fluorescence) were
uantified relative to all visible bacteria hybridizing with the
ub 338 FITC probe (green fluorescence). The methodol-
gy is reliable for semiquantitative assessment of bacterial
iofilm when more than 105 cfu/ml are present. Quantita-
ive assessment is possible when more than 107 cfu/ml are
resent.
easurements of cytokines, C-reactive protein, LPS,
nd immunoglobulin A (IgA)-anti-LPS. The serum con-
entrations of TNF-alpha and interleukin (IL)-6 were
easured by high-sensitivity enzyme-linked immunosor-
ent assay (ELISA, Quantikine HS, R&D, Minneapolis,
innesota). The lower limits of detection were 0.12 pg/ml
nd 0.039 pg/ml, respectively. Plasma concentrations of
igh-sensitivity C-reactive protein (hs CrP) were measured
y immunofluorescent assay (CRPus Kryptor, Brahms,
ennigsdorf, Germany). The lower limit of detection was
.06 g/ml. IgA-anti-LPS was measured by ELISA (21).
lasma LPS levels were assessed as described previously
sing a Limulus Amebocyte Lysate assay (Bio Whittaker,
alkerswill) (22).
tatistical analysis. Statistical analysis was performed us-
ng StatView 5.0 software (SAS Institute Inc., Cary, North
arolina). Normality of distribution was assessed using the
olmogorov-Smirnov test. Results are reported as mean 
EM (indicating normal distribution of data; statistical
omparisons were made using the unpaired t test) or median
25th, 75th percentiles] (indicating non-normal distribution
f data; statistical comparisons were made using the Mann-
hitney-U test). Frequencies were compared using the
hi-square test. Relationships between parameters were
ssessed using simple regression. A p value 0.05 was
onsidered significant in all analyses.
esults
here were no significant differences between control sub-
ects and CHF patients in terms of gender, age, height,
eight or body mass index (all p  0.05) (Table 1). As
xpected, CHF patients had a lower ejection fraction and
eak VO2.
mmunological assessments. Chronic heart failure pa-
ients showed higher plasma concentrations of TNF-alpha
3.0  0.2 pg/ml vs. 2.5  0.1 pg/ml), IL-6 (3.0 [1.6, 3.4]
s. 1.0 [0.8, 1.7] pg/ml), and higher blood leucocyte
oncentration compared with control subjects (all p 0.05).
-reactive protein did not significantly differ in patients and
ontrol subjects (2.1 [0.8, 3.6] vs. 1.1 [0.5, 3.4], p  0.4).
Patients compared with control subjects had higher
erum concentrations of immunoglobulin A-anti-LPS (128
96, 368] vs. 78 [41, 129] relative ELISA U/ml, p 0.005). ps expected, levels of free unbound endotoxin, measured in
subgroup of 10 patients and 12 control subjects, did not
ignificantly differ (2.3  0.09 vs. 2.2  0.04 endotoxin
/ml, p  0.6).
unctional alterations of the gut mucosa. We compared
ntestinal permeability and absorption in patients with CHF
nd control subjects to assess intestinal barrier function. The
ermeability index (PI) expressed as the urinary 5-h lactulose/
annitol ratio was increased in CHF patients compared with
ontrol subjects (PI: 0.023  0.001 vs. 0.017  0.001, p 
.006) (Fig. 1A). This indicates a 35% increase in intestinal
ermeability in CHF patients. Furthermore, CHF patients
howed a 29% decrease of D-xylose absorption compared
ith controls (26.7  3.0% vs. 37.4  1.4%, p  0.003)
Fig. 1B), which reflects a diminished activity of passive
arrier-mediated transport. Absorption of D-xylose in the
HF group showed no correlation with renal clearance (r
.1, p  0.7). Smokers (n  4) and nonsmokers showed
imilar permeability indexes and D-xylose recoveries in the
HF group (p  0.5).
Sucralose excretion was markedly increased in CHF
atients compared with control subjects (0.62  0.17% vs.
.20  0.06%, p  0.03). No difference was found in the
astroduodenal permeability between CHF patients and
ontrol subjects as measured by sucrose recovery (0.20 
.04% vs. 0.17  0.02%, p  0.5).
owel wall thickness. Chronic heart failure patients
howed increased bowel wall thickness in the terminal ileum
1.48 0.16 mm vs. 1.04 0.08 mm) representing the small
owel, ascending colon (2.32 0.18 mm vs. 1.31 0.14 mm),
ransverse colon (2.19  0.20 mm vs. 1.27  0.08 mm),
escending colon (2.59 0.18 mm vs. 1.43 0.13 mm), and
igmoid (2.97 0.27 mm vs. 1.64 0.14 mm) compared with
ontrol subjects (all p  0.01) (Figs. 2A and 2B).
Because diverticulosis might affect bowel wall thickness,
e reanalyzed the data for the sigmoid, excluding the 5
atients with diverticulosis. In this subgroup, sigmoid wall
hickness was larger in CHF patients than in control
ubjects (2.76 0.27 mm vs. 1.41 0.11 mm, p 0.0001).
n CHF patients, we did not find significant correlations of
owel wall thickness with age (for all intestinal segments
 0.3), peak VO2 (all p  0.2), LVEF (all p  0.2), or
YHA functional class (all p  0.2).
Bowel wall thickness in the ascending colon correlated
ith the blood concentration of leucocytes in CHF patients
r  0.49, p  0.045) (Fig. 3A). No such correlation was
ound with blood levels of hs CrP (r  0.27, p  0.29),
NF-alpha (r  0.1, p  0.70), and IL-6 (r  0.12, p 
.66). Bowel wall thickness in the sigmoid correlated with
lood levels of hs CrP (r  0.57, p  0.005) (Fig. 3B), but
ot with blood levels of TNF-alpha and IL-6 (r  0.34 and
.27, p  0.12 and 0.22, respectively).
There was a trend toward a higher thickness of the
scending colon in patients with a higher permeability in the
arge bowel, assessed by excretion of sucralose (r  0.50,
 0.051) (Fig. 3C).
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October 16, 2007:1561–9 Intestinal Function in Chronic Heart Failureacterial biofilm. Mean density of bacteria within mucus
as higher in CHF patients than in controls (10.4 108/ml
0.3 108/ml, 2,150 108/ml] vs. 0.01 108/ml [0.001
08/ml, 5  108/ml], p  0.007) (Figs. 4A to 4C). Bacteria
n CHF patients were more often adherent to the mucosa
in 70% vs. 36%, p 0.03) and bacterial biofilm ranged over
higher mean area of the biopsy (35.5  8.2% in CHF vs.
0.2  3.7% in control subjects, p  0.006).
As subjects with diverticulosis are known to be at higher
isk for bacterial overgrowth and inflammatory processes of
he sigmoid wall, we confirmed the findings excluding 5
HF patients and 6 control subjects with evidence of
ifferent degrees of diverticulosis on endoscopy: in CHF
atients without diverticulosis the mean concentration of
acteria was higher (29.0  108/ml [0.3  108/ml, 3,152 
08/ml]) than in controls (0.001 108/ml [0.001 108/ml,
.4  108/ml], p  0.0028). Bacterial adherence and
iofilm were also increased in CHF patients (adherence:
3% vs. 25%, p  0.03; biofilm-covered area: 33.1  9.3%
s. 3.4  2.0%, p  0.004).
In control subjects, bacteria of 16 different strains were
etected, whereas in CHF patients bacteria of 20 strains
ere found in varying frequencies. There was a trend for a
igher mean diversity of bacterial strains in patients com-
ared with controls (6 [4, 8.5] vs. 3.5 [0, 6] strains; p 
.055), but we could not identify a significant pattern.
The most frequent strains were Bacteroides/Prevotella in
9 of 20 patients and in 13 of 22 control subjects,
0
0.01
0.02
0.03
0.04
0.05
Controls (n=20) CHF (n=21)
p=0.006
CHF
controls
Permeability index (=PI)
A
Figure 1 Assessment of Small Intestinal Paracellular Permeabi
(A) Urinary lactulose/mannitol-index in chronic heart failure (CHF) patients (n  21
after ingestion of the test sugar drink. The results reflect increased small intestina
(B) Urinary recovery of orally administered D-xylose in CHF patients (n  22) comp
after ingestion of the test sugar drink. The results reflect reduced activity of carrieubacterium rectale group in 18 of 20 patients and in 13 of f2 control subjects, and Fusobacterium prausnitzii (Fprau) in
8 of 20 patients and in 12 of 22 control subjects, all
epresenting standing intestinal flora (all p  0.05). In the
ubgroup of 15 CHF patients and 9 control subjects with a
ucosal biofilm of 107 cfu/ml, the major strain-specific
omponents of bacterial mucosal biofilm could be quanti-
ed. We found a greater biofilm portion of Fprau in this
roup of patients compared with control subjects (15% [3,
0] vs. 25% [19, 39]; p  0.04). We found no significant
ifference in the proportion or absolute concentrations of
he other bacteria detected in this subgroup (all p  0.06).
iscussion
e report morphological and functional alterations of the
ut in CHF patients. All parts of the large bowel in CHF
atients display thickened walls compared with control
ubjects of similar age. Gut mucosa in CHF patients is
unctionally altered. Permeability is increased in both the
mall and large intestine for lactulose/mannitol and sucra-
ose, respectively, and passive carrier-mediated transport for
-xylose in CHF patients is diminished. The concentration
f bacteria in the sigmoidal mucosal biofilm and the extent
f the adherence are higher in CHF patients than in control
ubjects.
Altered bowel structure and function and impaired mu-
osal barrier function have not previously been described in
HF patients. An increased bowel wall thickness is a
0
10
20
30
40
50
60
70
CHF
controls
Urinary recovery of D-xylose [%]
Controls (n=21) CHF (n=22)
p=0.003
B
nd Passive Carrier-Mediated Transport
control subjects (n  20). Assessments were made from 5-h urine collection
eability of the gut mucosa in CHF patients compared with control subjects.
ith control subjects (n  21). Assessments were made from 5-h urine collection
ated transport of D-xylose.lity a
) and
l perm
ared w
r-medirequent finding in various conditions, such as acute isch-
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Intestinal Function in Chronic Heart Failure October 16, 2007:1561–9Figure 2 Bowel Wall Thickness in CHF Patients
Compared With Control Subjects
(A) Bowel wall thickness (assessed using transcutaneous abdominal sonogra-
phy, 12 MHz linear-array transducer) of terminal ileum, ascending colon, trans-
verse colon, descending colon and sigmoid in chronic heart failure (CHF)
patients compared with control subjects. Box plots indicate medians as well
as 25th and 75th percentiles. (B, C) Measurement of bowel wall thickness in
a healthy control subject (B) and a patient with CHF (C). Within the bowel wall,
3 layers can be differentiated. The hypoechoic layer next to the lumen corre-
sponds to the mucosa and the second echogenic layer corresponds to the sub-
mucosa. The third layer is again hypoechoic and corresponds to the muscularis
propria. Overall thickness of the bowel wall was measured from the first muco-
sal interface echo to the first serosal echo.Figure 3 Correlation Analysis
(A) Correlation of bowel wall thickness of the ascending colon with the concen-
tration of leucocytes in blood in chronic heart failure (CHF) patients compared
with control subjects. (B) Correlation of bowel wall thickness of the ascending
colon with the urinary recovery of sucralose in CHF patients compared with con-
trol subjects. (C) Correlation of bowel wall thickness of the sigmoid with log-
transformed concentration of high-sensitivity C-reactive protein (hs CrP) in
blood in CHF patients compared with control subjects.
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ypersensitivity (25). A greater bowel wall thickness in
HF may suggest the presence of bowel wall edema. That
here was a higher permeability of the colonic mucosa for
ucralose and a trend toward a positive correlation between
ucralose excretion and ascending colon wall thickness
uggests that the ascending colon is relevant to the patho-
hysiology of CHF. We cannot completely rule out influ-
nces of the patients’ long-term medication leading to
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Figure 4 Sigmoidal Mucosal Bacterial Biofilm
in CHF Patients Compared With Control Subjects
(A) Concentration of bacteria (bars represent median as well as 25th and 75th
percentiles) in the mucosal biofilm of biopsies taken during sigmoidoscopy.
Samples of chronic heart failure (CHF) patients (n  20) and control subjects
(n  22) were evaluated by fluorescence in situ hybridization (FISH). (B, C) Dig-
ital fluorescence pictures showing a higher concentration of bacteria in the
mucosal biofilm of the sigmoid as assessed by FISH in 1 representative CHF
patient (C) and a representative control subject (B).ncreases in permeability across the gut wall. On the other Cand, we believe that the use of in vivo sugar permeability
ests presents a diagnostic avenue that reflects the clinical
ituation in CHF patients receiving optimal conventional
edication.
The conditions that make the bowel wall less resistant to
ranslocation are many. Intramucosal acidosis, which occurs
n about 50% of patients with circulatory failure (6,26,27),
oints to an inadequate oxygen supply and intestinal isch-
mia (28). An increase in gastric intramucosal carbon
ioxide pressure occurs in recompensated CHF patients
ven at low levels of exercise (5). Diminished gut circulation
nd disturbed microcirculation may contribute to local edema
f the bowel wall and to malabsorption and barrier dysfunction
f the mucosa. Diminished passive carrier-mediated transport
f D-xylose, as found in this study, indicates a dysfunction of
ransport proteins in CHF and is a surrogate marker of
ntestinal ischemia (29). Similar dysfunctions may contribute
o nutritional perturbations that could promote the develop-
ent of cardiac cachexia (30,31).
Inadequate mucosal perfusion is known to increase intestinal
ucosal permeability (6). We detected a higher lactulose/
annitol ratio in CHF patients, reflecting increased perme-
bility of the epithelial layer of the gut. This permeability
ndex has been shown to be increased in burn injuries, in
atients undergoing cardiopulmonary bypass surgery, and in
atients who developed multiorgan failure, and is thought
o reflect transient intestinal hypoperfusion (7,9,32,33).
actulose is a nonmetabolizable disaccharide that crosses
he small intestinal epithelium by passive diffusion, mainly
hrough paracellular routes. Lactulose is a comparatively big
olecule (molecular weight 342.3 Dalton) that permeates
cross paracellular pathways that are normally limited,
hereas mannitol (molecular weight 182.2 Dalton) diffuses
eadily through cell membranes and paracellular routes
nvolving high-incidence small aqueous mucosal pores (34).
his test thereby assesses small intestinal paracellular integrity.
The morphological equivalent of the mucosal barrier
unction is the epithelial apical junctional complex, which
onsists of tight junctions and adherence junctions. It is
rone to several influencing factors, such as hypoxia and
roinflammatory cytokines. Proinflammatory cytokines
uch as interferon gamma and TNF-alpha have been shown
o disrupt the epithelial barrier function, consequently
nducing a state of hyperpermeability of the gut epithelium.
his is associated with internalization of apical junctional
omplex transmembrane proteins, as shown in studies of
olonic epithelial cell lines (35). We could not document a
elationship between markers of clinical status or inflamma-
ion and measures of intestinal permeability. Further studies
re needed to better understand the regulation of intestinal
ermeability in CHF. We did find a positive correlation
etween thickness of the ascending colon and leucocyte
ount in CHF patients. This may be concordant with the
rognostic value of an elevated white blood count for a
igher cardiovascular mortality and worse prognosis in
HF (36–40).
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Intestinal Function in Chronic Heart Failure October 16, 2007:1561–9The presence of mucosal barrier dysfunction that we
etected in CHF patients is in keeping with the hypothesis
f endotoxin translocation (4). In contrast to earlier reports,
e have directly investigated transmembrane permeability
f the gut mucosa. The findings of increased bowel wall
hickness, increased permeability index, lower passive
arrier-mediated transport of D-xylose, higher colonic per-
eability for sucralose, and higher concentrations of a
ostly adherent bacterial biofilm in these patients, provide
linical evidence that the intestine is pathologically altered
n CHF patients. These morphological and functional
hanges may result in decreased host defense against adher-
nt bacteria. When the liver is not capable of clearing portal
lood of LPS, then, as seen in CHF patients with edema-
ous decompensation, plasma levels of LPS are increased
11). One would not expect elevated systemic blood levels
f endotoxin in our study for 2 reasons. First, patients were
ot decompensated (11) and liver enzymes were not sig-
ificantly elevated. Second, LPS is usually bound to
ipopolysaccharide-binding proteins (41) and blood lipids
42) in an individual manner. These are the reasons that
ven patients with severe ulcerative colitis can display a
ormal amount of free LPS in systemic blood (43). How-
ver, absolute LPS blood load is difficult to assess, and
mmunoglobulin A–anti-LPS, which was higher in patients
ompared with control subjects, provides an alternative for
easuring endotoxin bioactivity and interaction in the
atient.
The finding of an increased intestinal concentration of
ostly adherent bacteria in CHF patients shows similarities
ith the pathology found in patients with inflammatory
owel disease where mucosal bacteria were found at con-
entrations 109/ml in 90% to 95% of patients and in only
5% of healthy controls (20). In these studies, adherent-
nvasive Escherichia coli were identified (44).
Most of the enteral bacteria are facultative pathogens.
ince the phenotypic properties of bacteria represented by
nterobacteriacae and other bacteria were not studied long-
erm, we cannot exclude the possibility that some of the
acteria found attached to the mucosa could be pathogenic.
owever, the high diversity of mucosal bacteria and the
ndividual character of their composition in each patient do
ot support that idea. More likely, the abnormal mucus
arrier allows intestinal bacteria to penetrate mucus and
ontact mucosa.
There are 2 ways by which adherent bacteria could
ontribute to chronic inflammation seen in CHF. First, the
ere adherence of a microbe to the intestinal epithelium
ithout invasion or translocation can induce mucosal cyto-
ine release and disrupt epithelial barrier function (45).
uminal hypoxia, hypercarbia, changes in local pH, and
edox state, as well as norepinephrine, are all known to be
otent activators of bacterial virulence in adherent bacteria
46). Second, microbial products of adherent bacteria could
nter the systemic circulation through the disrupted intes-
inal epithelial barrier. Recent studies on selective decon-amination of the gut in CHF patients have resulted in a
ecrease in some inflammatory markers underscoring the
otential importance of gut bacteria as one source of
nflammation in CHF (47).
onclusions
e have found significant morphological and functional
lterations of the intestine in CHF patients. These findings
re consistent with restricted intestinal perfusion and con-
equent mucosal edema, a higher intestinal permeability,
nd a lack of immunological defense with an augmented
acterial biofilm. Altered mucosal permeability and function
f the gut in CHF could contribute to chronic inflamma-
ion. Chronic heart failure is a multisystemic disorder
ssociated with alterations of intestinal function.
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